Neurocrine Biosciences (NBIX) EBT Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) EBT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 53.36% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.84% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -64.71% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 2.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -40.38% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 63.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -6.95% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 14.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.73% |
| Dec 31, 2025 | 26.63% |
| Sep 30, 2025 | 43.91% |
| Jun 30, 2025 | 106.81% |
| Mar 31, 2025 | -11.77% |
| Dec 31, 2024 | 139.76% |
| Sep 30, 2024 | 84.10% |
| Jun 30, 2024 | 19.69% |
| Mar 31, 2024 | 8.25% |
| Dec 31, 2023 | 68.13% |
| Sep 30, 2023 | 59.06% |
| Jun 30, 2023 | 13.48% |
| Mar 31, 2023 | -66.98% |
| Dec 31, 2022 | 45.09% |
| Sep 30, 2022 | 18.79% |
| Jun 30, 2022 | -34.76% |
| Mar 31, 2022 | 30.23% |
| Dec 31, 2021 | -39.85% |
| Sep 30, 2021 | -15.62% |
| Jun 30, 2021 | 127.18% |